- Home
- TRNR vs VIVS Comparison
TRNR vs VIVS Comparison
Compare TRNR & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNR
- VIVS
- Stock Information
- Founded
- TRNR 2017
- VIVS 2007
- Country
- TRNR United States
- VIVS United States
- Employees
- TRNR N/A
- VIVS N/A
- Industry
- TRNR Consumer Electronics/Appliances
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRNR Technology
- VIVS Health Care
- Exchange
- TRNR Nasdaq
- VIVS Nasdaq
- Market Cap
- TRNR 5.8M
- VIVS 4.7M
- IPO Year
- TRNR 2023
- VIVS N/A
- Fundamental
- Price
- TRNR $3.50
- VIVS $3.93
- Analyst Decision
- TRNR
- VIVS
- Analyst Count
- TRNR 0
- VIVS 0
- Target Price
- TRNR N/A
- VIVS N/A
- AVG Volume (30 Days)
- TRNR 369.8K
- VIVS 873.5K
- Earning Date
- TRNR 11-13-2025
- VIVS 11-07-2025
- Dividend Yield
- TRNR N/A
- VIVS N/A
- EPS Growth
- TRNR N/A
- VIVS N/A
- EPS
- TRNR N/A
- VIVS N/A
- Revenue
- TRNR $6,972,000.00
- VIVS $142,000.00
- Revenue This Year
- TRNR $578.14
- VIVS $42.38
- Revenue Next Year
- TRNR $130.65
- VIVS $15.42
- P/E Ratio
- TRNR N/A
- VIVS N/A
- Revenue Growth
- TRNR 373.32
- VIVS 94.52
- 52 Week Low
- TRNR $2.81
- VIVS $1.41
- 52 Week High
- TRNR $330.00
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- TRNR 42.94
- VIVS 64.83
- Support Level
- TRNR $3.10
- VIVS $3.29
- Resistance Level
- TRNR $3.81
- VIVS $5.30
- Average True Range (ATR)
- TRNR 0.51
- VIVS 0.63
- MACD
- TRNR 0.07
- VIVS 0.13
- Stochastic Oscillator
- TRNR 45.76
- VIVS 60.52
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.